{
    "ticker": "MIRM",
    "name": "Mirum Pharmaceuticals, Inc.",
    "description": "Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare gastrointestinal diseases. Founded in 2018 and headquartered in Foster City, California, Mirum focuses on addressing significant unmet medical needs in patients suffering from conditions such as Alagille syndrome and other cholestatic liver diseases. Their lead product candidate, Maralixibat, is a novel, oral therapy designed to improve the quality of life for patients with cholestatic liver disease by reducing pruritus (itching) and improving bile acid flow. Mirum's commitment to advancing science is underscored by its robust pipeline, which includes additional therapies targeting rare metabolic diseases and liver conditions. The company is dedicated to collaborative partnerships and research to discover new treatment options, ultimately aiming to enhance the lives of patients and their families. Mirum's work is guided by a patient-centric approach, ensuring that their developments are aligned with the needs and experiences of those they serve. As a company, Mirum strives to become a leader in the rare disease space by leveraging cutting-edge research and development practices to bring transformative therapies to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Foster City, California, USA",
    "founded": "2018",
    "website": "https://www.mirumpharma.com",
    "ceo": "Chris Peetz",
    "social_media": {
        "twitter": "https://twitter.com/mirumpharma",
        "linkedin": "https://www.linkedin.com/company/mirum-pharmaceuticals/"
    },
    "investor_relations": "https://investors.mirumpharma.com",
    "key_executives": [
        {
            "name": "Chris Peetz",
            "position": "CEO"
        },
        {
            "name": "Shawn C. K. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Maralixibat"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mirum Pharmaceuticals, Inc. | Innovating Rare Disease Therapies",
        "meta_description": "Learn about Mirum Pharmaceuticals, Inc., a leader in developing therapies for rare gastrointestinal diseases. Explore our innovative pipeline and patient-centered approach.",
        "keywords": [
            "Mirum Pharmaceuticals",
            "Maralixibat",
            "Rare Diseases",
            "Cholestatic Liver Disease",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Mirum Pharmaceuticals known for?",
            "answer": "Mirum Pharmaceuticals is known for developing therapies for rare gastrointestinal diseases, particularly cholestatic liver disease."
        },
        {
            "question": "Who is the CEO of Mirum Pharmaceuticals?",
            "answer": "Chris Peetz is the CEO of Mirum Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Mirum Pharmaceuticals headquartered?",
            "answer": "Mirum Pharmaceuticals is headquartered in Foster City, California, USA."
        },
        {
            "question": "What is Mirum's lead product candidate?",
            "answer": "Mirum's lead product candidate is Maralixibat, a therapy for cholestatic liver disease."
        },
        {
            "question": "When was Mirum Pharmaceuticals founded?",
            "answer": "Mirum Pharmaceuticals was founded in 2018."
        }
    ],
    "competitors": [
        "RPTX",
        "ALNY",
        "SRPT"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "AMGN",
        "BIIB"
    ]
}